Synthesis, chemical and enzymatic hydrolysis, and aqueous solubility of amino acid ester prodrugs of 3-carboranyl thymidine analogs for boron neutron capture therapy of brain tumors.
Synthesis, chemical and enzymatic hydrolysis, and aqueous solubility of amino acid ester prodrugs of 3-carboranyl thymidine analogs for boron neutron capture therapy of brain tumors.
复制标题
用于脑肿瘤硼中子捕获治疗的 3-碳硼基胸苷类似物的氨基酸酯前药的合成、化学和酶水解以及水溶性。
DOI:
10.1016/j.ejmech.2012.07.033
复制
发表时间:
2012
影响因子:
6.7
通讯作者:
Tjarks,Werner
中科院分区:
文献类型:
--
作者:
Hasabelnaby,Sherifa;Goudah,Ayman;Agarwal,HiteshK;abdAlla,MosaadSM;Tjarks,Werner
Various water-soluble l-valine-, l-glutamate-, and glycine ester prodrugs of two 3-Carboranyl Thymidine Analogs (3-CTAs), designated N5 and N5-2OH, were synthesized for Boron Neutron Capture Therapy (BNCT) of brain tumors since the water solubilities of the parental compounds proved to be insufficient in preclinical studies. The amino acid ester prodrugs were prepared and stored as hydrochloride salts. The water solubilities of these amino acid ester prodrugs, evaluated in phosphate buffered saline (PBS) at pH 5, pH 6 and pH 7.4, improved 48–6600 times compared with parental N5 and N5-2OH. The stability of the amino acid ester prodrugs was evaluated in PBS at pH 7.4, Bovine serum, and Bovine cerebrospinal fluid (CSF). The rate of the hydrolysis in all three incubation media depended primarily on the amino acid promoiety and, to a lesser extend, on the site of esterification at the deoxyribose portion of the 3-CTAs. In general, 3′-amino acid ester prodrugs were less sensitive to chemical and enzymatic hydrolysis than 5′-amino acid ester prodrugs and the stabilities of the latter decreased in the following order: 5′-valine > 5′-glutamate > 5′-glycine. The rate of the hydrolysis of the 5′-amino acid ester prodrugs in Bovine CSF was overall higher than in PBS and somewhat lower than in Bovine serum. Overall, 5′-glutamate ester prodrug of N5 and the 5′-glycine ester prodrugs of N5 and N5-2OH appeared to be the most promising candidates for preclinical BNCT studies.
登录
查看更多内容
DOI:
10.1021/jm990125i
发表时间:
1999
期刊:
Journal of medicinal chemistry.
影响因子:
--
作者:
Lunato,AJ;Wang,J;Woollard,JE;Anisuzzaman,AK;Ji,W;Rong,FG;Ikeda,S;Soloway,AH;Eriksson,S;Ives,DH;Blue,TE;Tjarks,W
通讯作者:
Tjarks,W
影响因子:
2.7
作者:
Keisuke Yamamoto;Yasuyuki Endo
通讯作者:
Yasuyuki Endo
DOI:
10.1016/s0168-3659(02)00413-3
发表时间:
2003
期刊:
Journal of controlled release : official journal of the Controlled Release Society
影响因子:
--
作者:
A. E. Thomsen;G. Friedrichsen;Arne Hagsten Sørensen;R. Andersen;C. Nielsen;B. Brodin;M. Begtrup;S. Frokjaer;B. Steffansen
通讯作者:
B. Steffansen
影响因子:
3.5
作者:
Sureshbabu Narayanasamy;B. Thirumamagal;Jayaseharan Johnsamuel;Youngjoo Byun;A. S. Al;E. Usova;Guirec Y. Cosquer;Junhua Yan;A. Bandyopadhyaya;R. Tiwari;S. Eriksson;W. Tjarks
通讯作者:
W. Tjarks
影响因子:
11.2
作者:
Al-Madhoun, AS;Johnsamuel, J;Eriksson, S
通讯作者:
Eriksson, S